首页> 美国卫生研究院文献>Journal of Pain Research >A randomized double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)
【2h】

A randomized double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)

机译:盐酸氢吗啡酮缓释片与盐酸羟可待酮缓释片对癌症疼痛的随机双盲研究:在日本癌症患者中的疗效和安全性(EXHEAL:氢吗啡酮延释氢吗啡酮用于缓解癌症疼痛的III期研究)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn Japan, there are limited options for switching opioid analgesics. Hydromorphone is an opioid analgesic that is routinely used instead of morphine for cancer pain; however, it is not yet available in Japan. The aim of this study was to assess the efficacy and safety of hydromorphone (DS-7113b) extended-release tablets in opioid-naïve patients with cancer pain not relieved by non-opioid analgesics.
机译:背景技术在日本,用于切换阿片类镇痛药的选择有限。氢吗啡酮是一种阿片类镇痛药,通常用于代替吗啡来治疗癌症疼痛。但是,它在日本尚不可用。这项研究的目的是评估氢吗啡酮(DS-7113b)缓释片在未使用非阿片类镇痛药缓解的无阿片类癌痛的癌症患者中的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号